Amgen Inc. Gain (Loss) on Extinguishment of Debt
Amgen Inc. (AMGN) reported Gain (Loss) on Extinguishment of Debt of $90.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-05
- Amgen Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Amgen Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was $90.00M, a 18.92% decline year-over-year.
- Amgen Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- Amgen Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $36.00M, a 56.10% decline year-over-year.
- Amgen Inc. gain (loss) on extinguishment of debt for fiscal 2025 was $264.00M, a 22.79% increase from fiscal 2024.
- Amgen Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $215.00M, a 4.44% decline from fiscal 2023.
- Amgen Inc. gain (loss) on extinguishment of debt for fiscal 2023 was $225.00M, a 188.46% increase from fiscal 2022.
- Amgen Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $78.00M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $90.00M 10-Q · filed 2026-08-05 | $90.00M derived: sum of 3 quarters · filed 2026-08-05 | $126.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $90.00M 10-Q · filed 2026-05-01 | $90.00M derived: sum of 2 quarters · filed 2026-05-01 | $126.00M derived: sum of 3 quarters · filed 2026-05-01 | $243.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $36.00M derived: sum of 2 quarters · filed 2026-02-13 | $153.00M derived: sum of 3 quarters · filed 2026-08-05 | $264.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $36.00M 10-Q · filed 2025-11-05 | $153.00M derived: sum of 2 quarters · filed 2026-08-05 | $264.00M 10-Q · filed 2025-11-05 | $264.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $117.00M 10-Q · filed 2026-08-05 | $228.00M 10-Q · filed 2026-08-05 | $228.00M derived: sum of 3 quarters · filed 2026-08-05 | $310.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $111.00M 10-Q · filed 2026-05-01 | $111.00M derived: sum of 2 quarters · filed 2026-05-01 | $193.00M derived: sum of 3 quarters · filed 2026-05-01 | $326.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $82.00M derived: sum of 2 quarters · filed 2026-02-13 | $215.00M derived: sum of 3 quarters · filed 2026-02-13 | $215.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $82.00M 10-Q · filed 2025-11-05 | $215.00M derived: sum of 2 quarters · filed 2025-11-05 | $215.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $133.00M 10-Q · filed 2024-08-07 | $133.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $133.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $225.00M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $182.00M 10-Q · filed 2023-10-31 | $295.00M derived: sum of 2 quarters · filed 2023-10-31 | $408.00M derived: sum of 3 quarters · filed 2023-10-31 | $486.00M derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | $113.00M 10-Q · filed 2023-08-04 | $226.00M derived: sum of 2 quarters · filed 2023-08-04 | $304.00M derived: sum of 3 quarters · filed 2023-08-04 | $382.00M derived: sum of 4 quarters · filed 2023-08-04 |
| 2023-03-31 | $113.00M 10-Q · filed 2023-04-28 | $191.00M derived: sum of 2 quarters · filed 2023-04-28 | $269.00M derived: sum of 3 quarters · filed 2023-04-28 | |
| 2022-12-31 | $78.00M 10-K · filed 2023-02-09 | $156.00M derived: sum of 2 quarters · filed 2023-02-09 | $78.00M 10-K · filed 2025-02-14 | |
| 2022-09-30 | $78.00M 10-Q · filed 2022-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |